



100 Lancaster Ave.
Suite R215
Wynnewood, PA 19096

610.645.6796

www.curedm.com

Contact: Donna Morrow
donna@curedm.com

CureDM, Inc. Announces the Appointment of John H. Dillon, II to the Board of Directors

Wynnewood, Pennsylvania, Oct. 26, 2006 -- CureDM, Inc, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin, announces the appointment of key advisor John H. Dillon, II to the Board of Directors. Founded in 2004 by Endocrinologists Claresa S. Levetan, MD, F.A.C.E and Rita El-Hajj, MD, F.A.C.E., CureDM pursues the goal of developing an alternative treatment for diabetes through islet restoration.

With the discovery of a new therapeutic candidate and an innovative approach to treatment, CureDM is very science driven. "We are so pleased to have John's expert guidance as we make our way through the early stages of development into the partnering process with our lead compound, Human ProIslet Peptide" states President and CEO Loraine V. Upham, formerly of Eli Lilly and Company and Merck and Company. "John has a deep understanding of the commercialization of pharmaceuticals through partnerships and invaluable experience on the in-licensing side of the process."

Mr. Dillon is currently a director at Encysive Pharmaceuticals, Inc, Houston, and director at NuPathe, Inc., Conshohocken, PA. He spent 22 years at SmithKline (now GlaxoSmithKline) where he was Vice President, New Business Development, for the U.S. Pharmaceutical group and then Vice President and Director, Worldwide Business Development reporting to the President, Worldwide Pharmaceuticals. In addition to his experience in deal making in the global pharmaceutical business, Mr. Dillon has extensive experience in marketing and promotions at SmithKline, and he directed sales and marketing activities for Omnicare CR (formerly IBAH, Inc.) a global clinical research organization with operations in 30 countries. His most recent marketing activity was as Senior Vice President, Marketing reporting to the CEO of Auxilium Pharmaceuticals, which became a public company in July 2004.

As a member of the CureDM Board of Directors, Mr. Dillon will provide help in both the development process and the eventual commercialization of Human proIslet Peptide (HIP). The lead compound has shown great promise in human pancreatic tissue culture studies and is in preclinical study now with the goal to achieve Investigational New Drug (IND) status through the FDA within the next 12 months.

About CureDM

CureDM, Inc., located on the Lankenau Institute for Medical Research campus in Wynnewood, Pennsylvania, has its roots in research conducted at the University of Pennsylvania. The company is developing a novel human peptide which stimulates the differentiation of adult pancreatic progenitor cells to regenerate insulin-producing islet structures providing a potential benefit to both type 1 and type 2 diabetic patients. Calvert is currently conducting "proof of efficacy" studies in its Scranton, PA. laboratories. For more information about CureDM, visit www.curedm.com.